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ABSTRACT 
This study was undertaken to assess the safety and protective 
efficacy against pertussis of a monocomponent pertussis toxoid 
vaccine in a society with hyperendemic pertussis. A total of 
3450 healthy infants from child health centers in the Goteborg 
area of Sweden were enrolled in a double-blind, randomized, 
placebo-controlled study. A combined diphtheria-tetanus vac- 
cine was given with or without pertussis toxoid (DTP-toxoids 
vs DT-toxoids) at 3, 5, and 12 months of age. One week after 
each vaccination a telephone interview about reactions was 
performed. From the day of the first vaccination a nasopha- 
ryngeal culture and acute and convalescent sera were obtained 
from study children and family members with cough lasting 7 
or more days. Coughing episodes were classified according 
to the World Health Organization (WHO) definition of pertussis. 
There were no serious reactions. There were slightly more local 
reactions with DTP-toxoids than with DT-toxoids. During the 
period of blinded follow-up, which began from 30 days after the 
third vaccination and lasted on average for 17.5 months, the 
general vaccine efficacy was 71% (95% confidence interval 
(Cl), 63-78%), and during an extended period of open follow- 
up performed during 6 months, vaccine efficacy was 77% (95% 
Cl, 65-85%). The efficacy against household exposure during 
the same periods was 73% (95% Cl, 61-83%) and 76% (95% 
Cl, 51-91%) respectively. A hydrogen-peroxide inactivated per- 
tussis toxoid vaccine that is easily standardized is safe and 
confers substantial protection against pertussis. 
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Since every foreign antigen has the potential for causing 
harmful effects, a vaccine should only contain essential 
components. Furthermore, a monocomponent vaccine 
should be easier to produce and standardize than multi- 
component vaccines, and there should be less risk for 
interaction with other vaccines administered concurrently. 
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Therefore, the efficacy of a pharmacologically inert per- 
tussis toxoid vaccine has been evaluated in a series of 
clinical trials.1,2 The trials were performed in Sweden, a 
country that has not provided general vaccination against 
pertussis since 1979, and in which there has been 
endemic pertussis with a cumulative incidence of 20% by 
the age of 3 years. 
This report presents data from a double-blinded, ran- 
domized, placebo-controlled trial, performed during 1991 
to 1994; it also includes data from an extended period of 
open follow-up. Data on the protection afforded by the 
monocomponent vaccine to children who were exposed 
to pertussis in the household are also presented. 
SUBJECTS AND METHODS 
Infants enrolled from child health centers in the Gote- 
borg area of western Sweden were randomized in a dou- 
ble-blind fashion to receive diphtheria-tetanus-pertussis 
toxoids (DTP-toxoids) or the same diphtheria-tetanus tox- 
oids alone (DT-toxoids). The hydrogen-peroxide inacti- 
vated pertussis toxoid was developed in the United States 
at the National Institute of Child Health and Human 
Development (NIH) and manufactured by AMVAX Inc. 
(Beltsville, MD, USA). Diphtheria-tetanus toxoids were 
manufactured by Statens Seruminstitut (Copenhagen, 
Denmark). One vaccine dose of 0.5 mL consisted of 25 
Lf diphtheria toxoid and 7 Lf tetanus toxoid with or with- 
out 40 kg of pertussis toxoid adsorbed onto 0.5 mg alu- 
minium hydroxide. The vaccines were indistinguishable 
in appearance. Vaccines were injected subcutaneously in 
the anterolateral part of the left thigh at 3, 5, and 12 
months of age, as is recommended for DT-toxoids in 
Sweden. 
From September 1991 to September 1992, the par- 
ents of 3450 of 5963 full-term, healthy, eligible children 
agreed to participate. One week after each vaccination 
a telephone interview was conducted, using a structured 
questionnaire. The parents of all children were inter- 
viewed after all vaccinations. 
From the day of the first vaccination the parents were 
instructed to contact the study nurse if anyone in the fam- 
ily coughed for 7 or more days. A nasopharyngeal culture 
and acute and convalescent sera were obtained from study 
children and family members with cough lasting 7 or more 
days. This report only contains data from cases of per- 
tussis fulfilling the World Health Organization (WHO) 
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definition and occurring either during the main period 
of blinded follow-up, which started 30 days after the third 
vaccination and lasted on average 17.5 months,’ or dur- 
ing an extended period of open follow-up for another 6 
months, from July 1994 until January 1995. 
The WHO defmition requires paroxysmal cough for 
21 or more days and at least one of the following: (1) pos- 
itive culture, (2) positive culture in family member with 
onset within 28 days before or after onset in the episode 
studied, and (3) significant rise in antibody against per- 
tussis toxin (PT) or filamentous hemagglutinin (FHA). A 
threefold rise in PT-IgG antibody titer or FHA-IgG anti- 
body titer was defined as significant. 
Vaccine efficacy was estimated as l-R, where R is 
the ratio of incidence rates in recipients of DTP- and DT- 
toxoids, and confidence intervals by exact calculation 
based on the conditional binomial distribution that fol- 
lows from the assumption of a Poisson distribution for 
cases in each group. Proportions were compared with a 
two-sided Fisher’s exact test and continuous variables 
with a two-sided permutation t-test. 
Household Exposure 
The first case of WHO-defined pertussis in a family was 
defined as the primary case. Cases of pertussis .with onset 
within 5 days after the onset in the primary case were 
defined as co-primary cases. Cases of pertussis with onset 
between 6 and 60 days after onset in the primary case 
were defined as secondary cases. 
Vaccine efficacy (LE) after household exposure was 
calculated as the proportion of cases prevented by vac- 
cination and estimated by the formula, VE = 1 - pJpc, 
where p, and p, are the proportions of study children in 
the vaccine and control groups, respectively, who had 
pertussis after household exposure. Confidence intervals 
were calculated by the likelihood score method. Pro- 
portions were compared with Fisher’s exact test with 
two-sided interval. 
Erythromycin Treatment 
The Swedish Board of Health and Welfare recommends 
erythromycin prophylaxis for infants less than 6 months 
old and for children with severe underlying disease who 
are exposed to pertussis. Early treatment of suspected 
pertussis with erythromycin is recommended for infants 
aged 6 to 11 months. Erythromycin is also recommended 
for older siblings of infants less than 12 months of age. 
Erythromycin is not recommended for healthy children 
over 1 year of age without younger siblings. These guide- 
lines were followed during the project. During the main 
period of blinded follow-up, erythromycin was given to 
4% of study children with WHO-defined pertussis. 
RESULTS 
Safety 
There were no serious vaccine-associated reactions in 
either of the two vaccine groups. No child exhibited 
symptoms of the hypotonic-hyporesponsive syndrome or 
afebrile seizures during the week after a vaccination. No 
child was withdrawn, by the parents or by the project 
leadership, because of an adverse reaction. Until the end 
of the main period of blinded follow-up 52 of 3450 
enrollees (30 DTP-toxoids, 22 DT-toxoids) were with- 
drawn without having reached the end-point of pertussis. 
The incidence of both fever and local reactions 
increased with the number of vaccinations (Table 1). The 
incidence of fever was nearly identical in the two vaccine 
groups both during the fast 48 hours and during the week 
following vaccination. Redness and swelling were some- 
what more common among the DTP-toxoids recipients 
than among the DT-toxoids recipients. Various general 
symptoms, such as irritability and crying, reported at the 
interview 1 week after each vaccination, occurred with 
equal frequency in both groups after each vaccination. 
Table 1. Reactions in Children Vaccinated with DTP-Toxoids and DT-Toxoids 
Vaccination Number 
Reaction 
1 2 3 
DTP DTP DTP 
(n = 17<24) (n =Y726) (n = 1708) (n =Y717) (n = 1692) (n =?687) 
Temperature within 48 hours 
238°C (%) 6 6 11 11 17 17 
240°C (%) 0.1 0 0.1 0.1 0.6 0.5 
Temperature within 7 days 
238°C (77) 8 8 14 14 21 20 
240°C (%) 0.1 0.1 0.3 0.1 1 1 
Local reactions within 7 days after vaccination 
Redness 220 mm (“Y&) 2 2 18* 11* 30* 24* 
Redness 260 mm (%) 0 0.1 0.1 0.1 4 3 
Swelling 220 mm (%) 2 2 13* 8* 24* 19* 
Swelling ~60 mm (%) 0 0.1 0.4 0.3 5* 3* 
*P < 0.01 when recipients of DTP-toxoids and of DT-toxoids are compared. 
150 International Journal of Infectious Diseases / Volume 1, Number 3, January 1997 




Cases* 72 vs. 240 
Cases/i 00 person y* 2.96 vs. 10.32 
Vaccine efficacy 71% 
95% Cl 63 - 78% 
Efficacy against household exposure 
Cases/exposed 19/82 vs. 52/60 
Attack rate* 23% vs. 87% 
Vaccine efficacy 73% 
95% Cl 61 - 83% 
*Recipients of DTP-toxoids vs. recipients of DT-toxoids. 
Cl = confidence interval. 
Open Period 
29vs. 110 
3.70 vs. 15.90 
77% 
65 - 85% 
5/25 vs. 15/l 8 
20% vs. 83% 
76% 
51-91% 
Protection against Pertussis 
During the main period of blinded follow-up, the gen- 
eral vaccine efficacy against WHO-defined pertussis was 
71% (95% CI, 63-78%), and during the extended period 
of open follow-up the vaccine efficacy was 77% (95% CI, 
65-85%) (Table 2). During the latter period, the inci- 
dence of pertussis in the control group was about 50% 
higher than during the blinded period. The efficacy of the 
vaccine in preventing pertussis after household exposure 
was similar to the general efficacy during both periods 
(see Table 2). Pertussis was significantly milder in vacci- 
nated than in unvaccinated children, and significantly 
fewer vaccinated children with pertussis were taken to 
a physician by their parents during the course of the dis- 
ease (Table 3). 
A significant increase of antibodies against FHA, an 
antigen not included in the vaccine, was found in more 
than 90% of WHO-defined cases of pertussis in both vac- 
cinated and unvaccinated children (Table 4). Pertussis 
toxin-serology, in contrast, had a significantly lower sen- 
sitivity in vaccinated children. Thus, efficacy estimates 
were higher after exclusion of the two case-defining cri- 
teria, FHA-serology and family exposure, which appear 
equally sensitive in recipients of DTP- and DT-toxoids 
(Table 5). In Tables 3 to 5 only data from the blinded 
period have been included, but similar results were 
obtained for the extended period (data not shown). 
Table 3. Comparison of Severity of WHO-Defined 
Pettussis* during the Blinded Period in Recipients 
of DTP-Toxoids and DT-Toxoids 
DTP 
(n = 72) (n _D2T40) P-Value 
Duration of symptoms (median values, d) 
Cough 49 59 <O.OOi 
Paroxysmal cough 42 51 <O.OOl 
Proportion of children with 
Vomiting 46% 78% 10.001 
Whooping attacks 39% 78% <O.OOl 
Visit to a physician 24% 42% <O.Oi 
*By definition 2 21 days of paroxysmal cough. 
Table 4. Comparison of Serologic Assays in Recipients of DTP- 




DTP-Toxoids DT-Toxoids P-Value 
24/66 (36%) 197/215 (92%) <O.OOl 
63/67 (94%) 206/223 (92%) NS 
Geometric mean titers in acute and convalescent sera 
PT-IgG 
Acute 1,562 29 
Convalescent 4,515 12,990 
FHA-IgG 
Acute 75 65 
Convalescent 4,377 5,546 






During a double-blind, randomized, and placebo-con- 
trolled trial of a monocomponent pertussis toxoid vac- 
cine, no serious vaccine-associated adverse events and 
no events contraindicating a subsequent vaccination 
occurred. The incidence of postvaccination fever was 
almost identical in the DTP- and DT-toxoids groups. 
A slight increase in local reactions was seen in the 
DTP-toxoids group compared to the DT-toxoids group in 
the efficacy trial, which might be expected when three, 
instead of two proteins are injected. In trials performed 
in the United States with the same DTP-toxoids as stud- 
ied here, the incidence of local reactions was lower than 
that observed in Sweden (Parke JC, Guerra E Personal 
communication, 1995). This difference may be attribut- 
able to the fact that the American infants received the vac- 
cine intramuscularly, whereas the Swedish infants 
received the vaccine subcutaneously. 
This study is the second one to demonstrate that a 
vaccine consisting of pertussis toxoid alone induces sub- 
stantial protection against pertussis.3 The duration of pro- 
tection induced by the new acellular pertussis vaccines 
is not known. In the present stucty three doses of a mono- 
component pertussis-toxoid vaccine induced an 
unchanged protection for at least 2 years after the third 
dose in a population with endemic pertussis and a high 
attack rate. 
Estimates of the efficacy of whole-cell pertussis vac- 
cines in studies of household secondary attack rates have 
in general been slightly lower than those obtained by 
Table 5. Changes in Efficacy Estimates of the Pettussis Toxoid 
Vaccine with Exclusion of Unbiased Diagnostic Criteria from the 
WHO Definition 
Number of Cases 
Group Number DTP- Toxoids DT-Toxoids Efhacy (95% Cl) 
1 72 240 71% (62-78%) 
2 52 229 78% (71-84%) 
3 46 220 80% (72-86%) 
Group 1 = All cases fulfilling WHO definition. 
Group 2 = Cases with only FHA-IgG increase excluded. 
Group 3 = Cases with only FHA-IgG increase and/or household contact 
excluded. 
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other methods.* In contrast, the present study of a mono- 
component pertussis-toxoid vaccine showed th,at the vac- 
cine efficacy after household exposure was similar to the 
general efficacy (see Table 2). The attack rate of pertus- 
sis in the control group of unvaccinated children in the 
present study was higher than SO%, which is’ in agree- 
ment with previous studies.5,6 A lower attack rate, 55%, 
was reported in the control group in a recent, open study 
of an acellular pertussis vaccine, in which erythromycin 
was given to a majority of primary and secondary cases.’ 
In contrast, in the present study, erythromycin was rarely 
given when a study child had received three vaccine 
doses. 
Several factors should be considered when the effi- 
cacy estimates of different acellular vaccines’ are com- 
pared, including diagnostic methods, disease burden in 
the population,* and erythromycin usage.’ The present 
study demonstrates the importance of unbiased labora- 
tory criteria for a reliable estimation of vaccine efficacy. 
Determination of IgG antibodies against PT in paired sera 
gave biased estimates of vaccine efficacy, because PT is 
included in the vaccine and all recipients of DTP-toxoids 
with pertussis had high pertussis toxin IgG antibody con- 
centrations already in the acute serum. In contrast, deter- 
mination of IgG antibodies against FHA, which was not 
a vaccine antigen, was highly sensitive (>90%) in both 
vaccinated and unvaccinated children. 
When comparing results of different prospective eff- 
cacy trials of acellular pertussis vaccines, it should be 
noted that the present trial is the only one that used serol- 
ogy to monitor responses to pertussis antigens not 
included in the vaccine. Eight acellular vaccines that have 
been tested in six other efficacy trials all include both PT 
and FHA.9-11 In at least one of these trials, household con- 
tact with a culture-confirmed case was not used as a diag- 
nostic criterion. l l 
If the two unbiased criteria of the WHO definition, 
FHA-serology and positive culture in a household con- 
tact, had not been used as diagnostic criteria, the calcu- 
lated vaccine efficacy in the present study would have 
been about 10% higher (see Table 5). Furthermore, if the 
case-finding in the present study had been based only on 
cases seen by a physician, the efficacy estimate using the 
WHO case definition for pertussis would have been 
around 85%. 
CONCLUSION 
This study showed that a monocomponent PT vaccine 
provided high protection against pertussis both for indi- 
viduals exposed in society and for those with household 
exposure. The individual protection during epidemic con- 
ditions was similar to that seen with monocomponent 
DT vaccines, when these were evaluated in susceptible 
populations during the 1940s and 1950~.‘~~~~ The question 
of whether mass vaccination with PT induces herd immu- 
nity and reduces spread of Bordetella pertussis is now 
the subject of a vaccination project that started in 1995 
in the Goteborg area of Sweden. All infants are offered 
three injections with DTP-toxoids at the ages of 3, 5, and 
12 months. Older children, who have already been vac- 
cinated against diphtheria and tetanus and who have 
been born during the 199Os, are offered three injections 
of PT alone at the same intervals as the infants. The aim 
is to vaccinate at least 80% of all children who have not 
had pertussis. The effect of the mass vaccination on the 
epidemiology of pertussis will be evaluated by the num- 
ber of positive cultures, numbers of hospitalizations due 
to pertussis, and interviews with parents of randomly 
selected children. 
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